Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report.
Agostino RivaDario CattaneoCarlo FiliceCristina GervasoniPublished in: International journal of STD & AIDS (2020)
We report here the case of a 32-year-old male with recent diagnosis of HIV that, 45 days after starting a single tablet regimen co-formulated with bictegravir, emtricitabine and tenofovir alafenamide (BIC/FTC/TAF), experienced severe epigastric pain radiating to the back, nausea, episodes of non-bloody non-bilious vomiting and anorexia. Laboratory examination showed a rise in lipase with no alterations in serum transaminases. Abdominal ultrasound revealed a non-homogeneous structure of the pancreatic parenchyma. A diagnosis of mild drug-related acute pancreatitis was made and BIC/FTC/TAF was immediately stopped. The association between the episode of acute pancreatitis and BIC/FTC/TAF was scored as probable according to the Naranjo causality scale.
Keyphrases
- antiretroviral therapy
- drug induced
- hiv infected
- hiv positive
- human immunodeficiency virus
- chemotherapy induced
- chronic pain
- magnetic resonance imaging
- hepatitis c virus
- high glucose
- hiv testing
- neuropathic pain
- pain management
- diabetic rats
- early onset
- men who have sex with men
- emergency department
- oxidative stress
- spinal cord injury
- ultrasound guided